BRCA2
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
First Direct-to-Consumer BRCA Test Authorized by FDA
First Direct-to-Consumer BRCA Test Authorized by FDA
Kerry Grens | Mar 6, 2018
The agency gave personal genomics company 23andMe the green light to screen samples for breast cancer–related genetic mutations.
Genetic Risk Factors for Breast Cancer Identified
Genetic Risk Factors for Breast Cancer Identified
Ashley P. Taylor | Oct 23, 2017
Researchers identify 72 novel genetic variants associated with breast cancer risk.
Q&A: Sequencing Newborns
Q&A: Sequencing Newborns
Tracy Vence | Oct 21, 2016
Members of the BabySeq Project discuss trial enrollment, preliminary findings.
BRCA Breakthroughs?
BRCA Breakthroughs?
Jenny Rood | Apr 21, 2015
Color Genomics announces a new, lower-cost BRCA mutation test, while Inserm and Quest Diagnostics reveal plans to pool patient data to investigate rare mutations.
<em>BRCA</em> Mutations Mapped
BRCA Mutations Mapped
Tracy Vence | Apr 8, 2015
In a large study, researchers find evidence to suggest that the type and location of a woman’s BRCA1/2 mutations may affect her cancer risk.
Yet Another Lawsuit over Genetic Tests
Yet Another Lawsuit over Genetic Tests
Tracy Vence | Jun 17, 2014
Myriad Genetics, the company originally behind tests for the cancer-associated BRCA mutations, is suing another competitor for patent infringement.
Speaking of Science
Speaking of Science
The Scientist Staff | Aug 1, 2013
August 2013's selection of notable quotes
Another Lawsuit over Genetic Tests
Another Lawsuit over Genetic Tests
Kate Yandell | Jul 11, 2013
Myriad Genetics, the company originally behind tests for the cancer-associated BRCA mutations, is suing two competitors for patent infringement.
Gene Patents Decision: Everybody Wins
Gene Patents Decision: Everybody Wins
Jeffrey M. Perkel | Jun 18, 2013
Last week’s Supreme Court decision to invalidate patents on human genes was a win for patients, independent researchers, and even the wider biotech industry.